Taylor Wealth Management Partners Bluebird Bio, Inc. Transaction History

Taylor Wealth Management Partners

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 04, 2020	SELL	$26.16 - $63.5 $317,844 - $771,525	-12,150 Closed	0 $0
Q4 2019 Jan 30, 2020	SELL	$46.96 - $61.67 $5,447 - $7,153	-116 Reduced 0.95%	12,150 $1.07 Million
Q3 2019 Oct 17, 2019	SELL	$59.47 - $93.1 $21,884 - $34,260	-368 Reduced 2.91%	12,266 $1.13 Million
Q2 2019 Jul 17, 2019	BUY	$75.84 - $105.21 $2,123 - $2,945	28 Added 0.22%	12,634 $1.61 Million
Q1 2019 May 14, 2019	SELL	$64.44 - $104.11 $3,866 - $6,246	-60 Reduced 0.47%	12,606 $1.98 Million
Q4 2018 Jan 14, 2019	SELL	$59.1 - $93.26 $4,432 - $6,994	-75 Reduced 0.59%	12,666 $1.26 Million
Q3 2018 Oct 23, 2018	SELL	$88.86 - $117.49 $1,510 - $1,997	-17 Reduced 0.13%	12,741 $1.86 Million
Q2 2018 Jul 27, 2018	SELL	$99.64 - $127.59 $757,064 - $969,428	-7,598 Reduced 37.33%	12,758 $2 Million
Q1 2018 Apr 11, 2018	SELL	$105.8 - $150.94 $278,994 - $398,028	-2,637 Reduced 11.47%	20,356 $3.48 Million
Q4 2017 Feb 01, 2018	SELL	$81.25 - $130.7 $89,375 - $143,770	-1,100 Reduced 4.57%	22,993 $4.1 Million
Q3 2017 Oct 13, 2017	BUY	$57.74 - $91.42 $1.39 Million - $2.2 Million	24,093	24,093 $3.31 Million

160

80M

525K

634K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $37.8M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Taylor Wealth Management Partners, based on Form 13F filings with the SEC.

Stay updated on Taylor Wealth Management Partners with notifications on news.